AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is £153.33.

Several analysts have issued reports on AZN shares. Citigroup lowered shares of AstraZeneca to a “buy” rating in a research report on Friday, July 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th.

AstraZeneca Price Performance

LON:AZN opened at £123.40 on Tuesday. The stock has a market cap of £191.38 billion, a P/E ratio of 18.58, a PEG ratio of 0.86 and a beta of 0.23. AstraZeneca has a one year low of £101.98 and a one year high of £157.32. The company has a fifty day moving average price of £135.93 and a 200 day moving average price of £140.97. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.